{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:31:29Z","timestamp":1790353889420,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07956-y","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:55:06Z","timestamp":1773939306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["EXT2 promotes sarcoma progression and immune evasion via the AKT\/c-Myc\/PD-L1 axis: a multi-omics and validation study"],"prefix":"10.1186","volume":"24","author":[{"given":"Haotian","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"7956_CR1","doi-asserted-by":"crossref","unstructured":"Coindre JM. New WHO classification of tumours of soft tissue and bone. Ann Pathol. 2012;32:S115\u201316.","DOI":"10.1016\/j.annpat.2012.07.006"},{"key":"7956_CR2","first-page":"1941","volume":"9","author":"EC Borden","year":"2003","unstructured":"Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, et al. Soft tissue sarcomas of adults: state of the translational science. CLIN Cancer Res. 2003;9:1941\u201356.","journal-title":"CLIN Cancer Res"},{"key":"7956_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei TA, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32:1348\u201365.","journal-title":"Ann Oncol"},{"key":"7956_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/pbc.23252","volume":"57","author":"A Ferrari","year":"2011","unstructured":"Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance Epidemiology and end results database. Pediatr Blood Cancer. 2011;57:943\u201349.","journal-title":"Pediatr Blood Cancer"},{"key":"7956_CR5","doi-asserted-by":"crossref","unstructured":"Hui JY. Epidemiology and etiology of Sarcomas. Surg Clin North Am. 2016;96:901\u201314.","DOI":"10.1016\/j.suc.2016.05.005"},{"key":"7956_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"7956_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell MOL Immunol. 2020;17:807\u201321.","journal-title":"Cell MOL Immunol"},{"key":"7956_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"7956_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/03008916211010214","volume":"107","author":"O Nigro","year":"2021","unstructured":"Nigro O, Ferrari A, Casanova M, Orbach D, Leruste A, Gatz SA, et al. Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAes and efficacy. Tumori. 2021;107:276\u201381.","journal-title":"Tumori"},{"key":"7956_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.ircmb.2016.02.009","volume":"325","author":"JP Li","year":"2016","unstructured":"Li JP, Kusche-Gullberg M. Heparan sulfate: biosynthesis, structure, and function. Int Rev Cell Mol Biol. 2016;325:215\u201373.","journal-title":"Int Rev Cell Mol Biol"},{"key":"7956_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2019.07.014","volume":"62","author":"V Masola","year":"2020","unstructured":"Masola V, Zaza G, Gambaro G, Franchi M, Onisto M. Role of heparanase in tumor progression: molecular aspects and therapeutic options. Semin Cancer Biol. 2020;62:86\u201398.","journal-title":"Semin Cancer Biol"},{"key":"7956_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12885-018-4597-x","volume":"18","author":"A Crespo","year":"2018","unstructured":"Crespo A, Garc\u00eda-Su\u00e1rez O, Fern\u00e1ndez-Vega I, Solis-Hernandez MP, Garc\u00eda B, Casta\u00f1\u00f3n S, et al. Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character. BMC Cancer. 2018;18:687.","journal-title":"BMC Cancer"},{"key":"7956_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","volume":"9","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-A review from the melanoma perspective and Beyond. Front Immunol. 2018;9:1474.","journal-title":"Front Immunol"},{"key":"7956_CR14","doi-asserted-by":"crossref","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68\u201377.","DOI":"10.5114\/wo.2014.47136"},{"key":"7956_CR15","doi-asserted-by":"crossref","unstructured":"Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41:D991\u201395.","DOI":"10.1093\/nar\/gks1193"},{"key":"7956_CR16","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607\u201313.","DOI":"10.1093\/nar\/gky1131"},{"key":"7956_CR17","doi-asserted-by":"crossref","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214\u201320.","DOI":"10.1093\/nar\/gkq537"},{"key":"7956_CR18","doi-asserted-by":"crossref","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","DOI":"10.1093\/nar\/gkv007"},{"key":"7956_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u201387.","journal-title":"Omics"},{"key":"7956_CR20","doi-asserted-by":"crossref","unstructured":"Powers RK, Goodspeed A, Pielke-Lombardo H, Tan AC, Costello JC. GSEA-InContext: identifying novel and common patterns in expression experiments. Bioinformatics. 2018;34:i555\u201364.","DOI":"10.1093\/bioinformatics\/bty271"},{"key":"7956_CR21","doi-asserted-by":"crossref","unstructured":"Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y, et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief BIOINFORM. 2023;24.","DOI":"10.1093\/bib\/bbac558"},{"key":"7956_CR22","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioportal. Sci Signal. 2013;6:l1.","DOI":"10.1126\/scisignal.2004088"},{"key":"7956_CR23","doi-asserted-by":"publisher","first-page":"1446522","DOI":"10.3389\/fonc.2024.1446522","volume":"14","author":"H Qin","year":"2024","unstructured":"Qin H, Qi T, Xu J, Wang T, Zeng H, Yang J, et al. Integration of ubiquitination-related genes in predictive signatures fo prognosis and immunotherapy response in sarcoma. Front Oncol. 2024;14:1446522.","journal-title":"Front Oncol"},{"key":"7956_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220.","journal-title":"Genome Biol"},{"key":"7956_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.","journal-title":"Genome Biol"},{"key":"7956_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u201357.","journal-title":"Nat Methods"},{"key":"7956_CR27","doi-asserted-by":"crossref","unstructured":"Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. ELIFE. 2017;6.","DOI":"10.7554\/eLife.26476"},{"key":"7956_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34.","journal-title":"Genome Med"},{"key":"7956_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7.","journal-title":"BMC Bioinf"},{"key":"7956_CR30","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"7956_CR31","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u201358.","journal-title":"Nat Med"},{"key":"7956_CR32","doi-asserted-by":"crossref","unstructured":"Geeleher P, Cox N, Huang RS. pRrophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9:e107468.","DOI":"10.1371\/journal.pone.0107468"},{"key":"7956_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"V Modhukur","year":"2018","unstructured":"Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. EPIGENOMICS-UK. 2018;10:277\u201388.","journal-title":"EPIGENOMICS-UK"},{"key":"7956_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semcancer.2019.11.009","volume":"61","author":"CD Steele","year":"2020","unstructured":"Steele CD, Pillay N. The genomics of undifferentiated sarcoma of soft tissue: progress, challenges and opportunities. Semin Cancer Biol. 2020;61:42\u201355.","journal-title":"Semin Cancer Biol"},{"key":"7956_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-022-02119-7","volume":"28","author":"T Kunisada","year":"2023","unstructured":"Kunisada T, Nakata E, Fujiwara T, Hosono A, Takihira S, Kondo H, et al. Soft-tissue sarcoma in adolescents and young adults. Int J Clin Oncol. 2023;28:1\u201311.","journal-title":"Int J Clin Oncol"},{"key":"7956_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5435\/00124635-200901000-00006","volume":"17","author":"NF Gilbert","year":"2009","unstructured":"Gilbert NF, Cannon CP, Lin PP, Lewis VO. Soft-tissue sarcoma. J Am Acad Orthop Surg. 2009;17:40\u201347.","journal-title":"J Am Acad Orthop Surg"},{"key":"7956_CR37","unstructured":"Al SA, Tebon PJ, Nguyen H, Chantharasamee J, Sartini S, Davarifar A, et al. The landscape of drug sensitivity and resistance in sarcoma. bioRxiv. 2023."},{"key":"7956_CR38","doi-asserted-by":"publisher","first-page":"844142","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, et al. Immunotherapy: reshape the tumor immune microenvironment. Front Immunol. 2022;13:844142.","journal-title":"Front Immunol"},{"key":"7956_CR39","doi-asserted-by":"crossref","unstructured":"Wieboldt R, L\u00e4ubli H. Glycosaminoglycans in cancer therapy. Am J Physiol Cell Physiol. 2022;322:C1187\u2013200.","DOI":"10.1152\/ajpcell.00063.2022"},{"key":"7956_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fimmu.2019.00875","volume":"10","author":"G Tzanakakis","year":"2019","unstructured":"Tzanakakis G, Neagu M, Tsatsakis A, Nikitovic D. Proteoglycans and immunobiology of cancer-therapeutic implications. Front Immunol. 2019;10:875.","journal-title":"Front Immunol"},{"key":"7956_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.oooo.2023.11.011","volume":"137","author":"A Selvan","year":"2024","unstructured":"Selvan A, Kannan B, Pandi C, Jayaseelan VP, Arumugam P. EXT2: a novel prognostic and predictive biomarker for head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2024;137:282\u201389.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"7956_CR42","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2174\/0113895575270904231129062137","volume":"24","author":"AK Wani","year":"2024","unstructured":"Wani AK, Singh R, Akhtar N, Prakash A, Nepovimova E, Oleksak P, et al. Targeted inhibition of the PI3K\/Akt\/mTOR signaling axis: potential for sarcoma therapy. Mini Rev Med Chem. 2024;24:1496\u2013520.","journal-title":"Mini Rev Med Chem"},{"key":"7956_CR43","doi-asserted-by":"publisher","first-page":"114394","DOI":"10.1016\/j.celrep.2024.114394","volume":"43","author":"S Adhikari","year":"2024","unstructured":"Adhikari S, Singh V, Nandi S, Ghosal M, Raj NS, Khanna J, et al. UBR7 in concert with EZH2 inhibits the TGF-\u03b2 signaling leading to extracellular matrix remodeling. Cell Rep. 2024;43:114394.","journal-title":"Cell Rep"},{"key":"7956_CR44","first-page":"1581122","volume-title":"A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: implications for biomarker discovery and therapeutic targeting","author":"H Qin","year":"2025","unstructured":"Qin H, Qi T, Liu M, Sheng W, Qian J, Weng J, et al. A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: implications for biomarker discovery and therapeutic targeting. Vol. 16. FRONT PHARMACOL; 2025. p. 1581122."},{"key":"7956_CR45","doi-asserted-by":"publisher","first-page":"108708","DOI":"10.1016\/j.biopha.2019.108708","volume":"114","author":"X Wu","year":"2019","unstructured":"Wu X, Cai J, Zuo Z, Li J. Collagen facilitates the colorectal cancer stemness and metastasis through an integrin\/PI3K\/AKT\/Snail signaling pathway. Biomed Pharmacother. 2019;114:108708.","journal-title":"Biomed Pharmacother"},{"key":"7956_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12010-022-03935-3","volume":"194","author":"W Liang","year":"2022","unstructured":"Liang W, Wang C, Wang J, Zhang M. Hsa_circ_0023984 regulates cell proliferation, migration, and invasion in Esophageal squamous cancer via regulating miR-1294\/PI3K\/Akt\/c-Myc pathway. Appl Biochem Biotechnol. 2022;194:1\u201316.","journal-title":"Appl Biochem Biotechnol"},{"key":"7956_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370.","journal-title":"Mol Cell"},{"key":"7956_CR48","doi-asserted-by":"publisher","first-page":"108899","DOI":"10.1016\/j.jnutbio.2021.108899","volume":"100","author":"JY Wang","year":"2022","unstructured":"Wang JY, Jiang MW, Li MY, Zhang ZH, Xing Y, Ri M, et al. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation. J NUTR Biochem. 2022;100:108899.","journal-title":"J NUTR Biochem"},{"key":"7956_CR49","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1158\/0008-5472.CAN-22-3023","volume":"83","author":"F Exposito","year":"2023","unstructured":"Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, et al. PTEN loss confers resistance to anti-PD-1 therapy in non-small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Res. 2023;83:2513\u201326.","journal-title":"Cancer Res"},{"key":"7956_CR50","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","volume":"143","author":"Y Gao","year":"2018","unstructured":"Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X, et al. IFN-\u03b3-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int. J Cancer. 2018;143:931\u201343.","journal-title":"Int. J Cancer"},{"key":"7956_CR51","doi-asserted-by":"publisher","first-page":"9769","DOI":"10.1038\/s41598-024-60539-z","volume":"14","author":"Y Lu","year":"2024","unstructured":"Lu Y, Cao N, Zhao M, Zhang G, Zhang Q, Wang L. Importance of CD8 Tex cell-associated gene signatures in the prognosis and immunology of osteosarcoma. Sci Rep. 2024;14:9769.","journal-title":"Sci Rep"},{"key":"7956_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/07357907.2022.2029474","volume":"40","author":"S Chen","year":"2022","unstructured":"Chen S, Zhu J, Wang P, Wan D, Cui X, Xu Y, et al. PD-L1 expression and intra-tumoral CD8(+) T lymphocytes in Esophageal Carcinosarcoma. Cancer Invest. 2022;40:337\u201347.","journal-title":"Cancer Invest"},{"key":"7956_CR53","doi-asserted-by":"publisher","first-page":"113282","DOI":"10.1016\/j.intimp.2024.113282","volume":"143","author":"H Qin","year":"2024","unstructured":"Qin H, Wang Q, Xu J, Zeng H, Liu J, Yu F, et al. Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma. Int Immunopharmacol. 2024;143:113282.","journal-title":"Int Immunopharmacol"},{"key":"7956_CR54","doi-asserted-by":"publisher","first-page":"1573694","DOI":"10.3389\/fphar.2025.1573694","volume":"16","author":"M Song","year":"2025","unstructured":"Song M, Xu J, Gui Z, Wu Y, Wang F, Sheng H, et al. Characterization of lysine crotonylation-related lncRnas for prognostic assessment and immune response in glioma. Front Pharmacol. 2025;16:1573694.","journal-title":"Front Pharmacol"},{"key":"7956_CR55","doi-asserted-by":"publisher","first-page":"112666","DOI":"10.1016\/j.intimp.2024.112666","volume":"139","author":"JP Li","year":"2024","unstructured":"Li JP, Liu YJ, Wang SS, Lu ZH, Ye QW, Zhou JY, et al. EBF1-COX4I2 signaling axis promotes a myofibroblast-like phenotype in cancer-associated fibroblasts (CAFs) and is associated with an immunosuppressive microenvironment. Int Immunopharmacol. 2024;139:112666.","journal-title":"Int Immunopharmacol"},{"key":"7956_CR56","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-2976","volume":"30","author":"K Luthria","year":"2024","unstructured":"Luthria K, Shah P, Caldwell B, Melms JC, Abuzaid S, Jakubikova V, et al. Single-cell profiling of sarcomas from archival tissue reveals programs associated with resistance to immune checkpoint blockade. CLIN Cancer Res. 2024;30:4530\u201341.","journal-title":"CLIN Cancer Res"},{"key":"7956_CR57","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","volume":"51","author":"MF Taddio","year":"2024","unstructured":"Taddio MF, Doshi S, Masri M, Jeanjean P, Hikmat F, Gerlach A, et al. Evaluating [(225)Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. Eur J Nucl Med Mol Imag. 2024;51:4026\u201337.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"7956_CR58","doi-asserted-by":"crossref","unstructured":"Cai Q, Que Y, Zhang X. Neoadjuvant immunotherapy in the evolving landscape of sarcoma treatment. J Immunother Cancer. 2024;12:e010074.","DOI":"10.1136\/jitc-2024-010074"},{"key":"7956_CR59","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.soc.2022.03.004","volume":"31","author":"C Moreno Tellez","year":"2022","unstructured":"Moreno Tellez C, Leyfman Y, D\u2019Angelo, Wilky BA, Dufresne A, et al. Immunotherapy in sarcoma. Where Do Things Stand? SURG ONCOL CLIN N Am. 2022;31:381\u201397.","journal-title":"Where Do Things Stand? SURG ONCOL CLIN N Am"},{"key":"7956_CR60","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.3390\/ijms24086926","volume":"24","author":"S Vanni","year":"2023","unstructured":"Vanni S, Fausti V, Fonzi E, Liverani C, Miserocchi G, et al. Unveiling the genomic basis of chemosensitivity in sarcomas of the extremities: an integrated approach for an unmet clinical need. Int J Mol Sci. 2023;24:6926.","journal-title":"Int J Mol Sci"},{"key":"7956_CR61","doi-asserted-by":"publisher","first-page":"1456649","DOI":"10.3389\/fimmu.2024.1456649","volume":"15","author":"H Qin","year":"2024","unstructured":"Qin H, Xu J, Yue Y, Chen M, Zhang Z, Xu P, et al. Disulfidptosis-related gene signatures as prognostic biomarkers and predictors of immunotherapy response in HNSCC. Front Immunol. 2024;15:1456649.","journal-title":"Front Immunol"},{"key":"7956_CR62","doi-asserted-by":"crossref","unstructured":"Yu JH, Liao LE, Xiao BY, Zhang X, Wu AW, Cheng Y, et al. Long-term outcomes of dMMR\/MSI-H rectal cancer treated with anti-PD-1-Based immunotherapy as curative-intent treatment. J Natl Compr Canc Netw. 2024;22.","DOI":"10.6004\/jnccn.2023.7096"},{"key":"7956_CR63","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. CELL. 2018;173:338\u201354.","journal-title":"CELL"},{"key":"7956_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. NATURE. 2015;523:231\u201335.","journal-title":"NATURE"},{"key":"7956_CR65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. NATURE. 2014;515:563\u201367.","journal-title":"NATURE"},{"key":"7956_CR66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u201328.","journal-title":"Science"},{"key":"7956_CR67","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. NATURE. 2018;554:544\u201348.","journal-title":"NATURE"},{"key":"7956_CR68","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u201369.","journal-title":"Science"},{"key":"7956_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fncel.2019.00327","volume":"13","author":"S Meng","year":"2019","unstructured":"Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Wu M. Epigenetics in Neurodevelopment: emerging role of circular RNA. FRONT Cell Neurosci. 2019;13:327.","journal-title":"FRONT Cell Neurosci"},{"key":"7956_CR70","doi-asserted-by":"crossref","unstructured":"Deng X, Sun X, Hu Z, Wu Y, Zhou C, Sun J, et al. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment. Faseb J. 2023;37:e23155.","DOI":"10.1096\/fj.202301343"},{"key":"7956_CR71","doi-asserted-by":"publisher","first-page":"1520070","DOI":"10.3389\/fimmu.2025.1520070","volume":"16","author":"J Xu","year":"2025","unstructured":"Xu J, You Z, Zhu Z, Liu M, Zhang Z, Xu P, et al. Integrative analysis of m7G methylation-associated genes prognostic signature with immunotherapy and identification of LARP1 as a key oncogene in head and neck squamous cell carcinoma. Front Immunol. 2025;16:1520070.","journal-title":"Front Immunol"},{"key":"7956_CR72","doi-asserted-by":"publisher","first-page":"1094793","DOI":"10.3389\/fgene.2023.1094793","volume":"14","author":"H Qin","year":"2023","unstructured":"Qin H, Sheng W, Zhang G, Yang Q, Yao S, Yue Y, et al. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. Front Genet. 2023;14:1094793.","journal-title":"Front Genet"},{"key":"7956_CR73","doi-asserted-by":"publisher","first-page":"109627","DOI":"10.1016\/j.biopha.2019.109627","volume":"121","author":"JY Wang","year":"2020","unstructured":"Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu J, et al. Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother. 2020;121:109627.","journal-title":"Biomed Pharmacother"},{"key":"7956_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12885-023-11798-y","volume":"24","author":"L Meng","year":"2024","unstructured":"Meng L, Shang H, Liu Q, Li Z, Wang X, Li Q, et al. Lnc-PSMA8-1 activated by GEFT promotes rhabdomyosarcoma progression via upregulation of mTOR expression by sponging miR-144-3p. BMC Cancer. 2024;24:79.","journal-title":"BMC Cancer"},{"key":"7956_CR75","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1038\/s41598-024-57594-x","volume":"14","author":"J Xu","year":"2024","unstructured":"Xu J, Guo K, Sheng X, Huang Y, Wang X, Dong J, et al. Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma. Sci Rep. 2024;14:7158.","journal-title":"Sci Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07956-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:02:05Z","timestamp":1784577725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07956-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7956"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07956-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study involving human participants was reviewed and approved by the Ethics Committee of Peking University Shenzhen Hospital (Approval No. 2024\u2013490). All procedures followed the 1964 Helsinki Declaration and its later amendments. Written informed consent was obtained from all participants. All animal experiments were approved by the Institutional Animal Care and Use Committee of Shenzhen Peking University\u2013The Hong Kong University of Science and Technology Medical Center (Approval No. 2025\u2013955), and conducted in accordance with the American Veterinary Medical Association (AVMA, 2020 edition) and the ARRIVE 2.0 guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"600"}}